ArticleTheranostics2018

Oncogenic TRIM31 confers gemcitabine resistance in pancreatic cancer via activating the NF-κB signaling pathway.

Chao Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.